EMA CHMP Grants Six Positive Opinions in October 2026, Including Oral GLP-1 Orforglipron and Two Biosimilars

Six positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) at its 12–15 October 2026 session expand the EU authorisation pipeline across oncology, metabolic disease, rare disease, and ophthalmology, each carrying distinct manufacturing, labelling, and post-approval commitments for sponsors preparing market entry dossiers.

The most commercially significant opinion covers Foundayo (orforglipron), an oral GLP-1 receptor agonist indicated for weight management and type 2 diabetes in adults. As a once-daily tablet, it enters a class dominated by injectables, placing new demands on solid-dose manufacturing lines and oral bioavailability validation relative to existing GLP-1 reference products. Manufacturers supplying this segment should anticipate heightened process validation scrutiny for tablet formulation and dissolution comparability.

In oncology, Rasonque (daraxonrasib) received a positive opinion for metastatic pancreatic adenocarcinoma following a phased review under EMA's Cancer Medicines Pathfinder project. Kizfizo (temozolomide), submitted via hybrid application, was recommended for glioblastoma multiforme in adults and malignant glioma in children; the hybrid pathway means QA teams should confirm that reference product data integration meets ICH Q10 pharmaceutical quality system expectations for lifecycle documentation.

Two biosimilar opinions, Fovlussea (ranibizumab) for retinal conditions and Neuzafy (filgrastim) for neutropenia, add to the EU biosimilar landscape. For plant heads managing biologics fill-finish or cold-chain logistics, these opinions signal near-term launch preparation windows and the associated sterility assurance and comparability exercise requirements under 21 CFR Part 211 equivalents in EU GMP Annex 1.

Yuviwel (navepegritide) for achondroplasia in children rounds out the six positive opinions, adding a paediatric rare disease product that will require age-appropriate formulation documentation and paediatric investigation plan compliance.

On the negative side, the CHMP confirmed its refusal of Yartemlea (narsoplimab) for HSCT-associated thrombotic microangiopathy following re-examination, closing the regulatory pathway for that indication without reversal. Two withdrawal decisions, Ibrance (palbociclib) for HR-positive, HER2-positive metastatic breast cancer maintenance and Truqap (capivasertib) for metastatic prostate cancer, reduce the near-term extension pipeline in oncology. Five already-authorised products, including AstraZeneca's pandemic influenza vaccine H5N1, Kyinsu, Talvey, Tryngolza, and Tukysa, received positive opinions for extensions of therapeutic indication.

Sponsors tracking the Foundayo and Rasonque authorisations should monitor the European Commission's formal decision timeline, typically issued within 67 days of a CHMP opinion, as the trigger point for national pricing, reimbursement negotiations, and GMP site activation.

Source: European Medicines Agency (EMA) via ema.europa.eu, 16 October 2026.